Jose Renju, Chandra Sharath, Puttabuddi Jaishankar H, Vellappally Sajith, Al Khuraif Abul-Aziz A, Halawany Hassan S, Abraham Nimmi B, Jacob Vimal, Hashim Mohamed
Dental Caries Research Chair, P.O. Box 60169, College of Dentistry, King Saud University, Riyadh 11545, Saudi Arabia.
Curr HIV Res. 2013 Sep;11(6):498-505. doi: 10.2174/1570162x11666131216125813.
The prevalence of orofacial and systemic manifestations and their association with drug therapy in pediatric HIV patients is scarce in the literature. The aim of the study was to determine the prevalence of oro-facial and systemic manifestations in HIV sero-positive children with and without highly active antiretroviral therapy (HAART). The study population consisted of 100 pediatric HIV patients (n=47 on HAART and n=53 not on HAART). The majority of the children (n=56) had at least one or more oro-facial manifestation associated with HIV. Oral candidiasis was the most common oral finding present in the HAART (14/33) and non-HAART groups (19/33). Recurrent aphthous ulcers was the only significant oral finding, present more in the HAART group. The percentage of children with upper respiratory tract infection was also more in the HAART group. The other lesions which were found to be significant were seborrheic dermatitis, pulmonary tuberculosis and otitis media. There was no significant difference in the participants' oral findings based on CD4 counts in the HAART and non- HAART groups. The prevalence of oral and systemic manifestations is a persistent feature associated with pediatric HIV, though of moderate intensity in those using HAART and may vary according to individual immune status.
儿科艾滋病毒患者口腔面部和全身表现的患病率及其与药物治疗的关联在文献中鲜有报道。本研究的目的是确定接受和未接受高效抗逆转录病毒治疗（HAART）的HIV血清阳性儿童口腔面部和全身表现的患病率。研究人群包括100名儿科艾滋病毒患者（47名接受HAART治疗，53名未接受HAART治疗）。大多数儿童（56名）至少有一项或多项与艾滋病毒相关的口腔面部表现。口腔念珠菌病是HAART组（14/33）和非HAART组（19/33）中最常见的口腔表现。复发性阿弗他溃疡是唯一具有显著差异的口腔表现，在HAART组中更为常见。HAART组上呼吸道感染儿童的比例也更高。其他被发现具有显著差异的病变包括脂溢性皮炎、肺结核和中耳炎。在HAART组和非HAART组中，基于CD4细胞计数的参与者口腔表现没有显著差异。口腔和全身表现的患病率是儿科艾滋病毒患者的一个持续特征，尽管在接受HAART治疗的患者中程度中等，并且可能因个体免疫状态而异。
